» Articles » PMID: 33632376

Screening for in Patients Admitted to Eight Intensive Care Units in England, 2017 to 2018

Abstract

Background is an emerging multidrug-resistant fungal pathogen associated with bloodstream, wound and other infections, especially in critically ill patients. carriage is persistent and is difficult to eradicate from the hospital environment.AimWe aimed to pilot admission screening for in intensive care units (ICUs) in England to estimate prevalence in the ICU population and to inform public health guidance.MethodsBetween May 2017 and April 2018, we screened admissions to eight adult ICUs in hospitals with no previous cases of in three major cities. Swabs were taken from the nose, throat, axilla, groin, perineum, rectum and catheter urine, then cultured and identified using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Patient records were linked to routine ICU data to describe and compare the demographic and health indicators of the screened cohort with a national cohort of ICU patients admitted between 2016 and 2017.ResultsAll screens for 921 adults from 998 admissions were negative. The upper confidence limit of the pooled prevalence across all sites was 0.4%. Comparison of the screened cohort with the national cohort showed it was broadly similar to the national cohort with respect to demographics and co-morbidities.ConclusionThese findings imply that colonisation among patients admitted to ICUs in England is currently rare. We would not currently recommend widespread screening for in ICUs in England. Hospitals should continue to screen high-risk individuals based on local risk assessment.

Citing Articles

Enhancing ICU spp. surveillance: a cost-effective approach focused on detection.

Nascimento T, Inacio J, Guerreiro D, Diaz P, Patricio P, Proenca L Front Cell Infect Microbiol. 2024; 14:1463456.

PMID: 39554808 PMC: 11564180. DOI: 10.3389/fcimb.2024.1463456.


Is routine screening for necessary in ICU?.

Sachu A, Sudersanan H, Sunny S, Mathew P, Kumar A, David A Iran J Microbiol. 2024; 16(5):708-715.

PMID: 39534293 PMC: 11551662. DOI: 10.18502/ijm.v16i5.16807.


Mortality and Associated Risk Factors in Patients With Candida auris: Insights From a Tertiary Care Hospital in Bahrain.

Alagha R, Sharaf A, Abdulkhaleq H, Acunin R, Saeed N Cureus. 2024; 16(9):e69699.

PMID: 39429292 PMC: 11489883. DOI: 10.7759/cureus.69699.


Outbreaks: Current Status and Future Perspectives.

De Gaetano S, Midiri A, Mancuso G, Avola M, Biondo C Microorganisms. 2024; 12(5).

PMID: 38792757 PMC: 11123812. DOI: 10.3390/microorganisms12050927.


The laboratory investigation, management, and infection prevention and control of : a narrative review to inform the 2024 national guidance update in England.

Jones C, Neill C, Borman A, Budd E, Cummins M, Fry C J Med Microbiol. 2024; 73(5).

PMID: 38771623 PMC: 11165919. DOI: 10.1099/jmm.0.001820.


References
1.
Eyre D, Sheppard A, Madder H, Moir I, Moroney R, Quan T . A Candida auris Outbreak and Its Control in an Intensive Care Setting. N Engl J Med. 2018; 379(14):1322-1331. DOI: 10.1056/NEJMoa1714373. View

2.
Chowdhary A, Sharma C, Meis J . Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017; 13(5):e1006290. PMC: 5436850. DOI: 10.1371/journal.ppat.1006290. View

3.
Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H . Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009; 53(1):41-4. DOI: 10.1111/j.1348-0421.2008.00083.x. View

4.
Vincent J, Rello J, Marshall J, Silva E, Anzueto A, Martin C . International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302(21):2323-9. DOI: 10.1001/jama.2009.1754. View

5.
Bentz M, Sexton D, Welsh R, Litvintseva A . Phenotypic switching in newly emerged multidrug-resistant pathogen Candida auris. Med Mycol. 2018; 57(5):636-638. DOI: 10.1093/mmy/myy100. View